| OCR Text |
Show Enhancing Providers' Readiness to Discuss Cannabis Amongst Patients With Neuropathology Chris Taylor DNP-FNP Student III Jenny Alderden Ph.D., APRN, ACRN, CCRN, CCNS, Jeanette Sherman MSN, FNP-C Key Findings: Two weeks following an evidenced based intervention 10 providers (91%) agreed they are better prepared to discuss cannabis with patients, 11(100%) felt their knowledge had improved on the Utah Medical Cannabis Act, 10 (91%) felt improved knowledge on the University of Utah Health Sciences policy on recommending cannabis, and 10 (91%) felt it improved their knowledge on potential clinical benefits. Background 4.5 Median Confidence in discussing cannabis with patients pre-intervention and two weeks post-intervention N=11 Pre-Intervention 4 2018, Proposition 2 passed, allows patients to use medical cannabis March 1, 2020 medical cannabis becomes available in Utah Availability and legal implications have left providers with significant knowledge deficits in discussing and prescribing cannabis. Purpose was to use available evidence to prepare providers Evidence-based intervention to enhance provider readiness was distributed Evidenced based intervention improved knowledge and provider comfort in discussing cannabis with their patients 3.5 3 Statistically significant difference in confidence level in answering questions about cannabis from patients with epilepsy pre/post intervention. W=3.5 p-value= 0.04 2.5 2 1.5 1 0.5 0 Parkinson's Methods Medical cannabis preintervention survey sent to providers who care for patients with neurological conditions within a major Utah Medical System Post-Intervention Alzheimer's Multiple Sclerosis Epilepsy Migraine/H.A. Essential Tremor Peripheral Neuropathy Figure 1. Median Confidence in Discussing Cannabis with Patients Pre-Intervention and Two Weeks Post-Intervention (2019). 6 Median agreeance regarding cannabis as it relates to medicine N=11 Pre-Intervention Post-Intervention Questions addressed to providers included utility for disease states, biases, changes in perception and baseline knowledge Statistically significant difference in if providers should be recommending cannabis: W=0, p-value = 0.03 & if phytocannabinoids may prevent seizureinduced neurotoxicity and seizure severity W=0, p-value= 0.05 Conclusions Providers agreed that cannabis has utility within medicine. Specifically, in reducing the fervor of seizures and preventing seizure induced neuronal damage 5 4 Timing was optimal, providers were prepared prior to enactment 3 Fourteen days after the module was distributed, a post-survey was provided Results Federal Law remains a barrier to providers recommending cannabis 2 This project can be reproduced and has the potential to benefit patients by enhancing provider knowledge 1 0 Should providers prescribe? Cannibinoid admin may reduce toxicity & limit seizure severity Figure 2. Median agreeance regarding cannabis as it relates to medicine and implications on the pharmacological effects of reducing seizure toxicity and limiting severity (2019). COLLEGE OF NURSING |
